Individual target pharmacokinetic/pharmacodynamic attainment rates among meropenem-treated patients admitted to the ICU with hospital-acquired pneumonia
Author:
Rohani Roxane123ORCID, Scheetz Marc H123ORCID, Donnelly Helen K4, Donayre Alvaro4, Kang Mengjia4, Diaz Estefani5, Dedicatoria Kay1, Hauser Alan R67, Ozer Egon A7, Nozick Sophia6, Qi Chao8, Pawlowski Anna E9, Neely Michael N1011, Misharin Alexander V4, Wunderink Richard G4, Rhodes Nathaniel J123ORCID, Abdala-Valencia Hiam, Alexander Michael J, Arnold Jason M, Bailey Joseph Isaac, Bartom Elizabeth T, Bharat Ankit, Bolig Thomas, Borkowski Nicole, Budinger G R Scott, Chandel Navdeep S, Clepp Rebecca K, Coleman John, Cuttica Michael J, Cybulski Thaddeus R, Dematte Jane E, Deters Joseph S, Fiala Justin A, Gadhvi Gaurav T, Gao Catherine A, Gates Khalilah L, Gatesy Samuel W M, Giri Ritika, Go Pearl D, Gottardi Cara J, Grant Rogan A, Green Stefan J, Gusman Elen, Guzman Estefany R, Han SeungHye, Hartmann Erica Marie, Horvath Curt M, Hukamdad Mishaal, Hyder Sydney M, Jain Manu, Joudi Anthony M, Kadar Rachel B, Kalhan Ravi, Kamp David W, Kandpal Manoj, Kidd David A, Kihshen Hermon, Klug Zasu M, Korth Erin A, Kruser Jacqueline M, Lawrence Romy, Leibenguth Emily M, Levenson Anne R, Gradone Lindsey D, Liu Gabrielle Y, Lomasney Jon W, Lombardo Theresa A, Lu Ziyan, Ludwig Amy, Mahmoud Ali, Malsin Elizabeth S, Markov Nikolay S, McQuattie-Pimentel Alexandra C, Meza Daniel, Morales Felix Leonardo, Morales-Nebreda Luisa, Morimoto Richard I, Mylvaganam Ruben J, Nannapaneni Prasanth, Amaral Luís A Nunes, Patel Radhika, Pesce Lorenzo L, Pickens Chiagozie O, Politanska Yuliya, Poor Taylor A, Prickett Michelle Hinsch, Querrey Melissa, Rasmussen Luke V, Ren Ziyou, Ridge Karen M, Rosenbaum Madeline L, Rosenberg Sharon R, Rowe Timothy, Russell Susan R, Sala Marc A, Schneider Daniel, Schroedl Clara J, Secunda Katharine, Seed Patrick C, Senkow Karolina J, Shamaly Todd, Shanes Elisheva D, Shen Jiaxian, Shilatifard Ali, Sichizya Lango, Singer Benjamin D, Smith Sean, Sporn Peter H S, Starren Justin, Stoeger Thomas, Sumner Jack, Swaminathan Suchitra, Sznajder Jacob I, Navarro Heliodoro Tejedor, Textor Lindsey N, Thakkar Sanket, Tomic Rade, Tran Betty, Vitale Kaitlyn, Wagh Ajay A, Walter James M, Wehbe Firas, Winter Deborah R, Wolfe Alexis Rose, Wolfe Lisa F, Yeldandi Anjana V,
Affiliation:
1. Midwestern University College of Pharmacy Downers Grove Campus , Downers Grove, IL , USA 2. Midwestern University College of Pharmacy Downers Grove Campus, Pharmacometrics Center of Excellence , Downers Grove, IL , USA 3. Department of Pharmacy, Northwestern Medicine , Chicago, IL , USA 4. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Feinberg School of Medicine, Northwestern University , Chicago, IL , USA 5. Robert H. Lurie Comprehensive Cancer Research Center, Feinberg School of Medicine, Northwestern University , Chicago, IL , USA 6. Department of Microbiology-Immunology, Northwestern University Feinberg School of Medicine , Chicago, IL , USA 7. Division of Infectious Diseases, Department of Medicine, Northwestern University Feinberg School of Medicine , Chicago, IL , USA 8. Department of Pathology, Feinberg School of Medicine, Northwestern University , Chicago, IL , USA 9. Clinical and Translational Sciences Institute, Feinberg School of Medicine, Northwestern University , Chicago, IL , USA 10. Laboratory of Applied Pharmacokinetics and Bioinformatics, The Saban Research Institute, Children’s Hospital of Los Angeles , Los Angeles, CA , USA 11. Keck School of Medicine, University of Southern California , Los Angeles, CA , USA
Abstract
Abstract
Objectives
Critical illness reduces β-lactam pharmacokinetic/pharmacodynamic (PK/PD) attainment. We sought to quantify PK/PD attainment in patients with hospital-acquired pneumonia.
Methods
Meropenem plasma PK data (n = 70 patients) were modelled, PK/PD attainment rates were calculated for empirical and definitive targets, and between-patient variability was quantified [as a coefficient of variation (CV%)].
Results
Attainment of 100% T>4×MIC was variable for both empirical (CV% = 92) and directed (CV% = 33%) treatment.
Conclusions
Individualization is required to achieve suggested PK/PD targets in critically ill patients.
Funder
NIH American Association of Colleges of Pharmacy
Publisher
Oxford University Press (OUP)
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)
Reference19 articles.
1. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society;Kalil;Clin Infect Dis,2016 2. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility;Roberts;Crit Care Med,2013 3. Augmented renal clearance and therapeutic monitoring of β-lactams;Udy;Int J Antimicrob Agents,2015 4. Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements;Ulldemolins;Antimicrob Agents Chemother,2015 5. Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa from the MYSTIC surveillance program: the OPTAMA Program, South America 2002;Kiffer;Diagn Microbiol Infect Dis,2004
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|